Trial
NCT00542828
Rabbit Anti-thymocyte Globulin in the Treatment of Patients With Low to Intermediate-1 Risk Myelodysplastic Syndrome
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Genzyme, a Sanofi Company
Collaborators
—
Condition
Myelodysplastic Syndrome (MDS)
Intervention
Thymoglobulin®, Rabbit Anti-thymocyte Globulin (rATG)
Why stopped
Study terminated due to slow enrollment.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-04-03